Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with Alzheimer’s disease
Aleksandra Klimkowicz-Mrowiec,1 Pawel Wolkow,2 Malgorzata Sado,3 Anna Dziubek,3 Joanna Pera,1 Tomasz Dziedzic,1 Andrzej Szczudlik,1 Agnieszka Slowik1 1Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, 2Department of Pharmacology, Jagiellonian University, School of Med...
Guardado en:
Autores principales: | Klimkowicz-Mrowiec A, Wolkow P, Sado M, Dziubek A, Pera J, Dziedzic T, Szczudlik A, Slowik A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c1887501bf014da5894b17470e85cfbf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang N, et al.
Publicado: (2018) -
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Richard A Hansen, et al.
Publicado: (2008) -
Use of Methylphenidate in Excessive Daytime Sleepiness in Alzheimer’s Patients Treated with Donepezil: Case Series
por: Bidzan L, et al.
Publicado: (2020) -
Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study
por: Zhang Z, et al.
Publicado: (2012) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013)